Genmab A/S (GNMSF) Stock Price, News & Analysis

Company Overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Key Stats

• Today's Range: $208.95 to $220.09
• 50-Day Range: $178.74 to $240.00
• 52-Week Range: $170.00 to $305.09
• Volume: 6 shs
• Average Volume: 3,022 shs
• Market Capitalization: $14.54 billion
• P/E Ratio: 12.56
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Genmab A/S Stock Analysis - MarketRank™

Genmab A/S scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Genmab A/S.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genmab A/S is 12.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.98.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genmab A/S is 12.56, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.81.

Price to Book Value per Share Ratio

Genmab A/S has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.11% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Genmab A/S has recently increased by 30.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genmab A/S does not currently pay a dividend.

Dividend Growth

Genmab A/S does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.11% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Genmab A/S has recently increased by 30.12%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.08

News Sentiment

Genmab A/S has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Genmab A/S this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genmab A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.54% of the stock of Genmab A/S is held by insiders.

GNMSF Stock Analysis - Frequently Asked Questions

How have GNMSF shares performed this year?

Genmab A/S's stock was trading at $207.38 on January 1st, 2025. Since then, GNMSF stock has increased by 6.1% and is now trading at $220.0875.
View the best growth stocks for 2025 here.

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) released its quarterly earnings results on Wednesday, February, 12th. The company reported $5.70 EPS for the quarter, beating the consensus estimate of $0.46 by $5.24. Genmab A/S had a net margin of 36.30% and a trailing twelve-month return on equity of 19.75%.

How do I buy shares of Genmab A/S?

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 2/12/2025
• Today: 5/04/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:GNMSF
• CIK: 1434265
• Web: www.genmab.com
• Phone: (457) 020-2728
• Fax: 45-7020-2729
• Employees: 1,660
• Year Founded: 1999

Profitability

• EPS (Most Recent Fiscal Year): $17.52
• Trailing P/E Ratio: 12.56
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1.14 billion
• Net Margins: 36.30%
• Pretax Margin: 42.57%
• Return on Equity: 19.75%
• Return on Assets: 16.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.25
• Quick Ratio: 5.24

Sales & Book Value

• Annual Sales: $3.12 billion
• Price / Sales: 4.66
• Cash Flow: $14.98 per share
• Price / Cash Flow: 14.69
• Book Value: $80.53 per share
• Price / Book: 2.73

Miscellaneous

• Outstanding Shares: 66,075,000
• Free Float: 65,057,000
• Market Cap: $14.54 billion
• Optionable: Not Optionable
• Beta: 1.10